| |
SUP
|
CTR
|
|---|
|
Variable
|
0 week
|
16 weeks
|
0 week
|
16 weeks
|
|---|
|
A. All subjects
| | | |
|
EPA (μg/mL)
|
62.5 ± 37.0
|
85.8 ± 50.0*, ***
|
87.7 ± 76.9
|
87.0 ± 77.2
|
|
DHA (μg/mL)
|
124.1 ± 63.8
|
149.9 ± 95.6
|
116.7 ± 52.9
|
118.4 ± 39.0
|
|
ARA (μg/mL)
|
142.6 ± 45.5
|
142.0 ± 47.3
|
150.7 ± 57.8
|
149.4 ± 44.0
|
|
α-Linolenic acid (μg/mL)
|
33.3 ± 17.2
|
39.0 ± 16.9*
|
31.6 ± 23.4
|
29.2 ± 12.9
|
|
n-3/n-6 ratio
|
0.24 ± 0.09
|
0.30 ± 0.11*, ***
|
0.28 ± 0.17
|
0.26 ± 0.12
|
|
EPA/AA ratio
|
0.47 ± 0.34
|
0.67 ± 0.51*, ***
|
0.72 ± 0.81
|
0.65 ± 0.62
|
|
B. Subgroup not prescribed EPA
| | | |
|
EPA (μg/mL)
|
55.4 ± 34.4
|
75.6 ± 47.7*, ***
|
48.4 ± 27.3
|
43.7 ± 21.9
|
|
EPA/AA ratio
|
0.36 ± 0.19
|
0.51 ± 0.26*, ***
|
0.31 ± 0.19
|
0.31 ± 0.20
|
-
SUP supplement group, CTR control group (no supplement), EPA eicosapentaenoic acid, DHA docosahexaenoic acid, ARA arachidonic acid, EPA/AA eicosapentaenoic acid/arachidonic acid
- *P < 0.05 versus CTR, ***P < 0.01 versus 0 week
